منابع مشابه
Improving access to depression care: descriptive report of a multidisciplinary primary care pilot service.
BACKGROUND Research has identified a need for improved depression care in primary care, while current United Kingdom (UK) health policy outlines standards for the management of the condition, including improved access to care. Innovative ways of working are needed to address these standards and provide better care. AIMS To pilot a multidisciplinary service for the management of depressed pati...
متن کاملMultidisciplinary Cancer Investigation: A New Path to Delve into the Ocean of Cancer Sciences
On behalf of the editorial and executive board members, it is my great pleasure to present the Multidisciplinary Cancer Investigation Journal. The rapid growth of medical sciences has necessitated the development of platforms to distribute and publish the results of research projects, and declare new discoveries. Among all medical disciplines, cancer is the one that involves the largest number...
متن کاملMultidisciplinary Cancer Investigation: A New Path to Delve into the Ocean of Cancer Sciences
On behalf of the editorial and executive board members, it is my great pleasure to present the Multidisciplinary Cancer Investigation Journal. The rapid growth of medical sciences has necessitated the development of platforms to distribute and publish the results of research projects, and declare new discoveries. Among all medical disciplines, cancer is the one that involves the largest number...
متن کاملAccess to Quality Cancer Care Workshop
Introduction As described in the Canadian Institutes of Health Research (CIHR) Five Year Strategic Plan for 2009-2013, one of the five CIHR strategic research priorities is to provide the evidence necessary to support a high quality, accessible and sustainable health care system. The CIHR Institute of Health Services and Policy Research (IHSPR) is the champion for research in this domain and ha...
متن کاملThe benefits of multidisciplinary prostate cancer care
STAMPEDE was initiated in 2005, docetaxel was the only approved agent that demon strated survival benefit in CRPC. As the pace of new prostate cancer drug develop ment has accelerated, and additional drugs with survival benefit have been approved, the plethora of ‘docetaxel plus’ studies have lost some relevance. Although STAMPEDE does not provide any support for the use of celecoxib in men w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 2004
ISSN: 0008-543X,1097-0142
DOI: 10.1002/cncr.20030